Chinese Capecitabine Market Investigation Report

0

Dublin, December 31, 2021 (GLOBE NEWSWIRE) – The “Chinese Capecitabine Market Investigation Report 2021-2025” the report was added to ResearchAndMarkets.com offer.

Capecitabine is a pyrimidine analog (pentoxycarbonyl-deoxy-cytosine nucleoside) that has anti-tumor activity to inhibit a variety of solid tumors, including breast and colon cancer. Capecitabine was developed by Roche. Its product, XELODA, was approved to enter the Chinese market in 2001. By 2020, there are several manufacturers in the capecitabine market in China.

According to the market research, sales of capecitabine in the Chinese market increased year on year from 2016 to 2019. Due to the impact of the COVID-19 pandemic on all diagnostic and medical services. hospital treatment, sales in 2020 declined to CNY 914 million. , a decrease of 9.31% year-on-year. The sales CAGR of capecitabine in the Chinese market from 2016 to 2020 is 1.21%.

The analyst expects that with the mitigation of the COVID-19 pandemic, sales of capecitabine in the Chinese market will experience restorative growth in 2021-2025. In 2020, the number of COVID-19 breast cancers worldwide reached 2.26 million and the number of colon cancers reached 1.93 million, both on the rise.

The number of breast and colon cancers in China will also increase in the future. Therefore, the sales volume of capecitabine, which is used to inhibit the anti-tumor activity of various solid tumors, will increase with the increase in the number of breast and colon cancer patients in China.

There is also room for sales to increase. In addition, by the end of 2020, a number of companies led by Chengdu Yuandong Biopharmaceuticals have already applied for approval of a generic drug for capecitabine. Over the next few years, more and more manufacturers will join the Chinese market. Sales volume and sales of capecitabine in China are expected to increase.

Topics covered:

  • The impact of COVID-19 on the Chinese capecitabine market
  • Chinese Capecitabine Sales Value 2016-2020
  • Competitive landscape of the Chinese capecitabine market
  • Capecitabine Price in China
  • China Capecitabine Price by Regions and Manufacturers
  • Analysis of factors affecting the development of the Chinese Capecitabine Market
  • Perspective of the Chinese Capecitabine Market from 2021 to 2025

Main topics covered:

1 Relevant concepts of capecitabine
1.1 Indications for capecitabine
1.2 History of the development of capecitabine in China
1.3 China Capecitabine Approval Information
1.4 The impact of COVID-19 on sales of capecitabine in China

2 Capecitabine sales in China, 2016-2020
2.1 Capecitabine sales value
2.1.1 Overall value of sales
2.1.2 Sales value by region
2.2 Capecitabine sales volume
2.2.1 Global sales volume
2.2.2 Sales Volume by Region
2.3 China Capecitabine Sales by Dosage Form, 2016-2020
2.3.1 Tablets
2.3.2 Analysis of other dosage forms

3 China Major Manufacturers Analysis of Capecitabine, 2016-2020
3.1 Major Manufacturers of Capecitabine Market Share Analysis
3.1.1 Market share by sales value
3.1.2 Market share by sales volume
3.2 Shanghai Roche Pharmaceuticals Co., Ltd.
3.2.1 Company profile
3.2.2 Sales of XELODA (Capecitabine from Shanghai Roche Pharmaceuticals Co., Ltd.) in China
3.3 Jiangsu Heng Rui Pharmaceutical Co., Ltd.
3.3.1 Company profile
3.3.2 Sales of Aibin (Capecitabine by Jiangsu Hengrui Medicine Co,. Ltd.) in China
3.4 Qilu Pharmaceutical Co., Ltd.
3.4.1 Company profile
3.4.2 Sales of Zuolun (Capecitabine by Qilu Pharmaceutical Co., Ltd.) in China
3.5 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3.5.1 Company Profile
3.5.2 Sales of Shoufu (Capecitabine by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.) in China
3.6 Hoffmann-La Roche inc
3.6.1 Company Profile
3.6.2 Sales of XELODA (Capecitabine from Hoffmann-La Roche Inc) in China

4 Capecitabine Price of Different Manufacturers in China, 2020-2021
4.1 Shanghai Roche Pharmaceuticals Co., Ltd. (XELODA)
4.2 Jiangsu Hengrui Medicine Co, Ltd. (Aibine)
4.3 Qilu Pharmaceutical Co., Ltd. (Zuolun)
4.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Shoufu)
4.5 Hoffmann-La Roche Inc (XELODA)

5 China Capecitabine Drug Market Outlook, 2021-2025
5.1 Factors influencing the development of the Chinese capecitabine market
5.1.1 The impact of COVID-19 on the Chinese capecitabine market
5.1.2 Market Drivers and Opportunities
5.1.3 Market threats and challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast

Companies mentioned

  • Shanghai Roche Pharmaceuticals Co., Ltd. (XELODA)
  • Jiangsu Hengrui Medicine Co, Ltd. (Aibine)
  • Qilu Pharmaceutical Co., Ltd. (Zuolun)
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Shoufu)
  • Hoffmann-La Roche Inc (XELODA)

For more information on this report, visit https://www.researchandmarkets.com/r/d45er9


        
Share.

Comments are closed.